NEW YORK (GenomeWeb News) – Genetics-based diagnostic company GigaGen today said that it has received four grants totaling more than $1 million to develop and validate its Cell-Seq technology to aid in the prediction of immune flares in transplant recipients and autoimmune patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.